Radioconjugate development

Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI

Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

Pharma's Almanac

Accelerating Product Development

What strategies are being employed to accelerate product development and commercialization without compromising quality?

Pharma's Almanac

Roundtable

What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?

Pharma's Almanac

Clinical and Commercial Manufacturing

Reach the Patient Quicker with GBI’s Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI

Roundtable: Artificial Intelligence

In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?

Pharma's Almanac

Disruptive Technology

What do you view as the most disruptive or transformational technology or development on the horizon?

Pharma's Almanac

Biomanufacturing

New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!

Danielle Alvarez

Pharma's Almanac

Opioid Conjugate Vaccines

Vaccines Present a Novel Strategy for Opioid Overdose Prevention

Muctarr Sesay, Ph.D.

GBI

Speed to Clinic

Leveraging Experience to Reduce Timelines for IND-Enabling Activities

Muctarr Sesay, Ph.D.; Andrew Majdoch, M.Sc.

GBI

Theranostics

Theranostic Manufacturing Solutions

Muctarr Sesay, Ph.D.

GBI